![](https://endpts.com/wp-content/uploads/2023/05/AP23130658270848-scaled.jpg)
David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)
Lilly gears up trio of PhIII trials for its oral GLP-1 amid Novo Nordisk, Pfizer competition
As Novo Nordisk and Pfizer disclose some data on their oral weight loss drugs in Phase III and II, respectively, Eli Lilly is beefing up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.